ARDX
Ardelyx, Inc.
ARDX has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ARDX overall, supported by stronger fundamentals and stronger modeled upside.
ARDX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ARDX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARDX PE Valuation
ARDX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 253x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ARDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ARDX to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ARDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | — |
| Q3 2026 | -$0.23 | +$0.01 |
| Q2 2026 | -$0.23 | +$0.01 |
| Q1 2026 | -$0.24 | -$0.01 |
| Q4 2025 | -$0.26 | -$0.09 |
| Q3 2025 | -$0.24 | +$0.06 |
| Q2 2025 | -$0.24 | +$0.03 |
| Q1 2025 | -$0.23 | +$0.05 |
| Q4 2024 | -$0.17 | +$0.13 |
ARDX is still losing money, but far less than before: $0.23 per share over the past year, against $1.13 at its worst in mid-2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ARDX on earnings quality, reporting a profit while its opponent remains loss making.
ARDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $127.7M | +16% |
| Q2 2026 | $120.9M | +24% |
| Q1 2026 | $94.5M | +27% |
| Q4 2025 | $125.2M | +7.8% |
| Q3 2025 | $110.3M | +12% |
| Q2 2025 | $97.7M | +33% |
| Q1 2025 | $74.1M | +61% |
| Q4 2024 | $116.1M | +238% |
ARDX's revenue has grown year over year for 11 quarters in a row: $128M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.1% | -1.1 points |
| Q2 2026 | -10% | +4.5 points |
| Q1 2026 | -35% | +14 points |
| Q4 2025 | 4.1% | -2.9 points |
| Q3 2025 | 4.2% | +2 points |
| Q2 2025 | -15% | +3.9 points |
| Q1 2025 | -49% | +4.6 points |
| Q4 2024 | 7% | +88 points |
ARDX's operating margin was 3.1% last quarter, down 1.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ARDX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ARDX on profitability, with a higher operating margin.
ARDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +939% |
| Q2 2026 | -$6.4M | +$19.6M |
| Q1 2026 | -$32.3M | +$6.5M |
| Q4 2025 | $20.6M | +123% |
| Q3 2025 | $209K | -43% |
| Q2 2025 | -$26M | -$6.5M |
| Q1 2025 | -$38.8M | -$2.9M |
| Q4 2024 | $9.2M | +$18M |
ARDX has burned cash in most quarters: −$16M over the past year, against −$55M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ARDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +1.9M shares |
| 1 year | +3.3% | +8.1M shares |
| 3 years | +9.7% | +22.1M shares |
| 5 years | -30% | -108M shares |
ARDX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ARDX Net Leverage
ARDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ARDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 9.8 | Oversold |
ARDX's weekly RSI is 30 (neutral) and its Stochastic is 10 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ARDX PE vs Healthcare Sector
ARDX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ARDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.15 | 1% below |
| 20 week MA | $3.88 | 20% below |
| 50 week MA | $5.32 | 41% below |
| 100 week MA | $5.17 | 40% below |
| 200 week MA | $5.30 | 41% below |
ARDX is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ARDX on trend strength, trading above more of its moving averages.
ARDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.86 | $1.72 | -7.5% |
| 2021 | $1.72 | $1.18 | -31% |
| 2022 | $1.18 | $2.41 | +104% |
| 2023 | $2.41 | $6.20 | +157% |
| 2024 | $6.20 | $5.21 | -16% |
| 2025 | $5.21 | $5.74 | +10% |
| 2026 YTD | $5.74 | $3.12 | -46% |
ARDX has finished lower in three of the last six years. It's down 46% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ARDX on returns for 2026, with the stronger performance.